Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21164
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCheung, Ada S-
dc.contributor.authorZajac, Jeffrey D-
dc.contributor.authorWynne, Katie-
dc.contributor.authorErasmus, Jaco-
dc.contributor.authorMurray, Sally-
dc.date2019-07-04-
dc.date.accessioned2019-08-08T06:30:31Z-
dc.date.available2019-08-08T06:30:31Z-
dc.date.issued2019-08-
dc.identifier.citationMedical Journal of Australia 2019; 211(3): 127-133en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21164-
dc.description.abstractRising demand for gender-affirming hormone therapy mandates a need for more formalised care of transgender and gender diverse (TGD) individuals in Australia. Estimates suggest that 0.1-2.0% of the population are TGD, yet medical education in transgender health is lacking. We aim to provide general practitioners, physicians and other medical professionals with specific Australian recommendations for the hormonal and related management of adult TGD individuals. Hormonal therapy is effective at aligning physical characteristics with gender identity and in addition to respectful care, may improve mental health symptoms. Masculinising hormone therapy options include transdermal or intramuscular testosterone at standard doses. Feminising hormone therapy options include transdermal or oral estradiol. Additional anti-androgen therapy with cyproterone acetate or spironolactone is typically required. Treatment should be adjusted to clinical response. For biochemical monitoring, target estradiol and testosterone levels in the reference range of the affirmed gender. Monitoring is suggested for adverse effects of hormone therapy. Preferred names in use and pronouns should be used during consultations and reflected in medical records. While being TGD is not a mental health disorder, individualised mental health support to monitor mood during medical transition is recommended. Gender-affirming hormone therapy is effective and, in the short term, relatively safe with appropriate monitoring. Further research is needed to guide clinical care and understand long term effects of hormonal therapies. We provide the first guidelines for medical practitioners to aid the provision of gender-affirming care for Australian adult TGD individuals.en_US
dc.subjectEndocrine systemen_US
dc.subjectEndocrinologyen_US
dc.titlePosition statement on the hormonal management of adult transgender and gender diverse individualsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleMedical Journal of Australiaen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationDiabetes and Endocrinology, Hunter New England Health, Newcastle, NSW, Australiaen_US
dc.identifier.affiliationGender Clinic, Monash Health, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationSexual Health Service, Royal Perth Hospital, Perth, WA, Australiaen_US
dc.identifier.doi10.5694/mja2.50259en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3933-5708en_US
dc.identifier.orcid0000-0001-5257-5525en_US
dc.identifier.pubmedid31271465-
dc.type.austinJournal Articleen_US
local.name.researcherCheung, Ada S
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Aug 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.